Processing your request

please wait...

Case Page


Case Status:    DISMISSED    
On or around 12/24/2020 (Notice of voluntarily dismissal)

Filing Date: October 14, 2020

According to the Complaint, Proteostasis Therapeutics, Inc. is a clinical stage biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat cystic fibrosis.

Plaintiff brings this stockholder class action on behalf of himself and all other public stockholders of Proteostasis, Inc. for alleged violations of the Securities and Exchange Act of 1934 and for alleged breaches of fiduciary duty as a result of the Individual Defendants’ efforts to sell the Company to Yumanity Therapeutics, Inc.

On August 24, 2020, the Company issued a press release announcing the Proposed Transaction.

On September 23, 2020, Defendants caused to be filed the Registration Statement with the SEC in an effort to solicit stockholders to vote their Proteostasis shares in favor of the Proposed Transaction. The Complaint alleges that the Registration Statement omits and/or misrepresents material information concerning, among other things: (a) the sales process and in particular certain conflicts of interest for management; (b) the financial projections for Proteostasis and Yumanity, utilized in any financial analyses purporting to support the Proposed Transaction, if any; and (c) the data and inputs underlying the financial analyses purporting to support the Proposed Transaction performed by Proteostasis’s financial advisor.

This case was voluntarily dismissed on December 24, 2020.


Sector: Healthcare
Industry: Biotechnology & Drugs
Headquarters: United States


Ticker Symbol: PTI
Company Market: NASDAQ
Market Status: Public (Listed)

About the Company & Securities Data

"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
COURT: S.D. New York
DOCKET #: 20-CV-08578
JUDGE: Hon. Edgardo Ramos
DATE FILED: 10/14/2020
CLASS PERIOD END: 10/14/2020
  1. Brodsky & Smith, LLC (New York)
No Document Title Filing Date
—Reference Complaint Complaint Related Data is not available
—Related District Court Filings Data is not available